MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, introduced the MAST platform, a proprietary automated cell culture system, and simultaneously announced a strategic partnership with Lonza to deploy it. The arrangement ties a supplier's hardware directly to a CDMO's commercial lines, a structure less common than a simple vendor purchase agreement. The outcome of the partnership as of mid-2024 was not publicly established. But the deal's terms and the platform's technical specifications provide a clear picture of what both companies intended to achieve.
MAST automates cell culture workflows that have historically required extensive manual labor. In standard cell therapy operations, technicians transfer cells between vessels, feed them, and monitor growth by hand. MAST replaces those steps with a closed, automated system that controls media exchange, cell passaging, and environmental conditions. The system is intended to reduce contamination risk, lower labor costs, and improve batch-to-batch consistency.
The platform is built around modular hardware and software. MilliporeSigma described it as a fully integrated solution configurable for adherent and suspension cultures, which covers most cell therapy modalities. The automation layer includes sensors for pH, dissolved oxygen, and cell density, with software that adjusts parameters in real time. Every step is logged, creating the digital record regulators expect for advanced therapy manufacturing.
What the MAST Platform Automates
The MAST platform targets the core bottleneck in cell therapy: the manual handling of living cells. In a typical run, cells must be fed, split, and monitored at precise intervals. Errors in timing or contamination can ruin an entire batch. For a treatment that costs hundreds of thousands of dollars per dose, a single failure is significant. MAST replaces those manual steps with a robotic system that moves plates and flasks between incubators, liquid handlers, and analyzers.
MilliporeSigma said the platform can handle multiple cell lines simultaneously, a critical feature for contract manufacturers working with several clients at once. The system uses single-use consumables, eliminating cleaning and sterilization between runs. That design reduces turnaround time and lowers the capital expenditure required for stainless steel bioreactors and autoclaves.
The software layer, called MAST Control, provides a user interface for designing and executing cell culture protocols. Operators create a recipe for a specific cell type, schedule feeds and passages, and monitor the process remotely. The system generates an audit trail for every action, supporting compliance with good manufacturing practice (GMP) requirements. MilliporeSigma positioned the platform as a way for CDMOs and therapy developers to scale output without proportionally increasing headcount.
How MAST Fits Into Lonza's Workflow
Lonza operates multiple facilities worldwide that manufacture cell therapies for clients. Its existing workflow involves manual steps for early-stage clinical production and some automated systems for later-stage commercial supply. MAST was designed to integrate into that infrastructure rather than requiring a greenfield facility.
The partnership called for MilliporeSigma to install MAST units at Lonza sites and provide training and technical support. Lonza would then use the platform to manufacture cell therapies for its clients. The specific facility where the platform was first deployed was not disclosed. The timeline for deployment and commercial readiness was also not revealed. As of May 2024, the operational status of the partnership was unknown.
Integration Requirements
Integration into Lonza's workflow likely required the MAST platform to interface with the company's existing manufacturing execution systems (MES) and quality management software. MilliporeSigma said the platform uses standard communication protocols. The extent of integration with Lonza's specific systems was not detailed. The partnership structure suggests that MilliporeSigma was not simply selling hardware; it was acting as a technology partner responsible for making the system work within Lonza's operational framework.
Cell Therapy Modalities the Platform Supports
The MAST platform supports both adherent and suspension cultures, covering the two main categories of cell therapy production. Adherent cells, such as mesenchymal stem cells (MSCs), grow attached to a surface and require passaging with enzymes. Suspension cells, including many immune cell treatments like CAR-T and natural killer (NK) cells, grow floating in media. They are typically easier to scale.
MilliporeSigma said the platform can be configured for both types, serving a broad range of therapy developers. The modular design allows users to swap out modules for different steps: centrifugation, washing, or concentration. That flexibility is important for CDMOs like Lonza, which need to accommodate varying client workflows without building dedicated lines for each one.
The platform also supports viral vector production. Viral vectors genetically modify cells in many advanced treatments. Vector manufacturing shares the same challenges as cell culture: aseptic handling and precise environmental control. By covering both cell culture and viral vector work, MAST positions itself as a platform that can support the entire upstream workflow for a range of advanced therapy modalities.
The Problem MAST Solves: Cost, Scalability, and Labor
Cell therapy manufacturing is expensive and difficult to scale. A single dose of a commercial CAR-T treatment can cost more than USD 100,000 to produce. Much of that cost comes from the manual labor required to handle living cells. The workflow is also prone to variability. Two operators may produce slightly different results, complicating regulatory approval and batch release.
MAST addresses those problems by replacing manual steps with automated, closed-system processing. The platform reduces the number of operators needed per batch. It eliminates the variability introduced by human handling. It also cuts the risk of microbial contamination, a major cause of batch failure. A single contamination event can destroy a batch and delay a patient's treatment.
Scalability is another target. Cell therapies often start with small clinical trials requiring only a few batches per year. Successful treatments must scale to hundreds or thousands of doses. Manual workflows do not scale linearly. Adding more operators introduces coordination complexity and quality control overhead. MAST scales by adding more modules rather than more people. That changes the cost structure of production as volumes increase.
Commercial Terms and Exclusivity
The financial value of the partnership between MilliporeSigma and Lonza was not disclosed. It is not known whether MilliporeSigma receives a per-batch royalty, a fixed license fee, or a combination of both. The partnership may involve MilliporeSigma supplying the hardware and software while Lonza provides the facilities and operational expertise. The exact revenue-sharing or pricing model was not made public.
Whether the partnership is exclusive or non-exclusive was also not stated. An exclusive deal would make Lonza the only CDMO with access to MAST for a defined period or geography. A non-exclusive arrangement would allow MilliporeSigma to sell or license the platform to other CDMOs and therapy developers, potentially expanding its market beyond the Lonza relationship. The absence of a public statement on exclusivity suggests the companies either did not consider it a key selling point or chose to keep the terms confidential.
Geographic and Financial Unknowns
Geographic limitations were not disclosed. Lonza has facilities in Europe, North America, and Asia. The partnership could cover all of them or a subset. The lack of detail on financial and contractual terms makes it difficult to assess the deal's economic significance for either company. Still, the structure of a supplier-CDTO partnership with integrated deployment is notable regardless of the specific numbers.
Competitive Positioning
The partnership positions MilliporeSigma as more than a reagent and consumables supplier. By offering a proprietary automation platform and partnering directly with a leading CDMO, the company moves into the equipment and software space, competing with established automation providers like Cytiva, Thermo Fisher Scientific, and Sartorius. For Lonza, the deal provides access to a dedicated automation platform without the internal development cost. It allows the CDMO to offer clients a more standardized and scalable production workflow.
Other CDMOs, including Catalent, WuXi AppTec, and Fujifilm Diosynth Biotechnologies, have invested in their own automation and digitalization efforts. Lonza's partnership with MilliporeSigma gives it a platform integrated with a supplier's broader portfolio of cell culture media, reagents, and single-use systems. That integration could reduce the time needed to qualify new workflows and transfer them between sites.
The competitive advantage depends on execution. If MAST delivers on its claims of reduced labor costs, improved consistency, and faster scale-up, Lonza could win more contracts from therapy developers who want a reliable manufacturing partner. For MilliporeSigma, a successful deployment at Lonza would serve as a reference case to sell MAST to other CDMOs and biopharma companies. As of May 2024, no public data on the platform's performance at Lonza was available. The partnership's actual impact on the advanced therapies market remained unproven.
Key Facts
- Platform Name: MAST (MilliporeSigma Automation and Software Technologies)
- Owner: MilliporeSigma, the U.S. and Canada life science business of Merck KGaA
- Partner: Lonza, a global CDMO headquartered in Switzerland
- Function: Proprietary automated cell culture manufacturing system
- Status as of: May 2024 (outcome unknown)
